Fate Therapeutics Inc（FATE）财务数据FATEFate Therapeutics Inc

Evaluating the bottom line, Fate Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1495.39%, while the net margin is -1448.56%. These profitability ratios, combined with a Return on Equity (ROE) of -60.75%, provide a clear picture of how effectively FATE converts its operational activities into shareholder value.

In the context of the broader market, FATE competes directly with industry leaders such as RNAC and IVVD. With a market capitalization of $279.18M, it holds a significant position in the sector. When comparing efficiency, FATE's gross margin of 100.00% stands against RNAC's 100.00% and IVVD's 91.09%. Such benchmarking helps identify whether Fate Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Fate Therapeutics has a gross margin of 100%, indicating no cost of goods sold, but it has been reporting significant net losses, with a net income of -30,159,000 USD in Q2 2026. The current ratio is 4.85, suggesting good short-term liquidity.